ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
1-Year Return
26.77%
This Quarter Return
+12.59%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$366M
AUM Growth
+$143M
(+64%)
Cap. Flow
+$97.7M
Cap. Flow
% of AUM
26.67%
Top 10 Holdings %
Top 10 Hldgs %
59.33%
Holding
282
New
118
Increased
36
Reduced
44
Closed
29
Top Buys
| 1 |
Alpha Architect 1-3 Month Box ETF
BOXX
|
$33.9M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$25.5M |
| 3 |
Protagonist Therapeutics
PTGX
|
$16.9M |
| 4 |
Roivant Sciences
ROIV
|
$16.2M |
| 5 |
Cytokinetics
CYTK
|
$15.9M |
Top Sells
| 1 |
Keros Therapeutics
KROS
|
$23.2M |
| 2 |
Viking Therapeutics
VKTX
|
$19.7M |
| 3 |
Royalty Pharma
RPRX
|
$18.2M |
| 4 |
Merck
MRK
|
$7.09M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$6.35M |
Sector Composition
| 1 | Healthcare | 82.64% |
| 2 | Communication Services | 1.24% |
| 3 | Financials | 0.78% |
| 4 | Materials | 0.59% |
| 5 | Consumer Discretionary | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Pfizer
PFE
$139B
| $2.95M | 0.67% |
106,342
+88,942
| +511% | +$2.47M |
|
27
Vanguard Ultra-Short Bond ETF
VUSB
$5.46B
| $2.74M | 0.62% |
55,206
+5,000
| +10% | +$248K |
|
28
JPMorgan Ultra-Short Income ETF
JPST
$33B
| $2.72M | 0.62% |
54,000
+5,000
| +10% | +$252K |
|
29
iShares Short Treasury Bond ETF
SHV
$20.7B
| $2.71M | 0.61% |
24,500
| – | – |
|
30
Solid Biosciences
SLDB
$428M
| $2.71M | 0.61% |
203,204
+202,204
| +20,220% | +$2.69M |
|
31
WisdomTree Floating Rate Treasury Fund
USFR
$18.8B
| $2.67M | 0.6% |
53,000
-3,000
| -5% | -$151K |
|
32
Cellectar Biosciences
CLRB
$15.8M
| $2.56M | 0.58% |
21,418
-24,518
| -53% | -$2.93M |
|
33
OmniAb
OABI
$229M
| $2.45M | 0.56% |
451,485
-26,686
| -6% | -$145K |
|
|
CNTA
34
Centessa Pharmaceuticals
CNTA
$2.13B
| $2.34M | 0.53% |
+206,856
| New | +$2.34M |
|
35
Regeneron Pharmaceuticals
REGN
$60.3B
| $2.21M | 0.5% |
+2,300
| New | +$2.21M |
|
36
iBio
IBIO
$15.9M
| $2.19M | 0.5% |
+600,000
| New | +$2.19M |
|
37
Corteva
CTVA
$49.3B
| $2.16M | 0.49% |
37,400
-20,600
| -36% | -$1.19M |
|
38
Beyond Air
XAIR
$11.1M
| $2.1M | 0.48% |
+60,241
| New | +$2.1M |
|
39
Immunovant
IMVT
$2.86B
| $1.96M | 0.45% |
60,763
-73,362
| -55% | -$2.37M |
|
40
Ligand Pharmaceuticals
LGND
$3.26B
| $1.96M | 0.44% |
+26,800
| New | +$1.96M |
|
41
SPDR SSGA Ultra Short Term Bond ETF
ULST
$614M
| $1.93M | 0.44% |
47,684
-13,580
| -22% | -$550K |
|
42
Spyre Therapeutics
SYRE
$1.04B
| $1.88M | 0.43% |
49,500
+43,060
| +669% | +$1.63M |
|
43
Schrodinger
SDGR
$1.41B
| $1.72M | 0.39% |
63,586
+61,586
| +3,079% | +$1.66M |
|
44
Spero Therapeutics
SPRO
$119M
| $1.59M | 0.36% |
926,929
-140,782
| -13% | -$242K |
|
45
uniQure
QURE
$965M
| $1.52M | 0.35% |
+292,850
| New | +$1.52M |
|
46
Apellis Pharmaceuticals
APLS
$3.56B
| $1.51M | 0.34% |
+25,700
| New | +$1.51M |
|
47
Eli Lilly
LLY
$666B
| $1.45M | 0.33% |
+1,865
| New | +$1.45M |
|
48
Teva Pharmaceuticals
TEVA
$21.3B
| $1.43M | 0.33% |
101,626
-9,700
| -9% | -$137K |
|
|
NGM
49
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $1.3M | 0.29% |
+816,581
| New | +$1.3M |
|
|
50
Viking Therapeutics
VKTX
$2.96B
| $1.18M | 0.27% |
14,401
-239,750
| -94% | -$19.7M |
|